Member access

4-Traders Homepage  >  Shares  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Dr. Reddy's Laboratories Limited    DRREDDY   INE089A01023

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Dr. Reddy's Laboratories Limited : Dr. Reddy’s Announces the Launch of Zoledronic Acid Injection

03/05/2013 | 04:15am US/Eastern
Recommend:
0

Hyderabad, India, March 05, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa® (zoledronic acid) 4 mg/5 mL Injection in the US market on March 4, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (4 mg/5 mL).

Dr. Reddy's Zoledronic Acid Injection 4 mg/5mL is available in a single use vial of concentrate.

Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses -Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:
www.drreddys.com

Zometa® is a registered trademark of Novartis AG

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com/ +91-40-66834297
Saunak Savla at saunaks@drreddys.com/ +91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

Media:
S Rajan at rajans@drreddys.com/ +91-40-49002445

distributed by
Recommend :
0
React to this article
Latest news on DR. REDDY'S LABORATORIES L
3d agoDR. REDDY'S LABORATORIES LIMITED : quaterly earnings release
5d ago DR REDDY LABORATORIES : . Reddy's to Release Q1 FY15 Results on July 30, 2014
07/15 DR REDDY LABORATORIES : DRL chiefs' pay rises despite steady revenues
07/14 DR REDDY LABORATORIES : To rebrand for international appeal
07/13 DR REDDY LABORATORIES : . Reddy's Introduces Duloxetine Delayed-Release Capsules..
07/11DJIndian Shares Continue to Fall on Profit-Taking
07/11 DR. REDDY'S LABORATORIES LIMITED : ex-dividend day for annual dividend
07/04 DR REDDY LABORATORIES : Drl to develop products for integrated markets
07/03 Indian, us generic firms launch coaliation for affordable care
07/02 DR REDDY LABORATORIES : . Reddy's Unveils Duloxetine Delayed-Release Capsules US..
Advertisement
Chart
Duration : Period :
Dr. Reddy's Laboratories L Technical Analysis Chart | DRREDDY | INE089A01023 | 4-Traders
Income Statement Evolution
Dr. Reddy's Laboratories L : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF